Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms
Neoplasm Metastasis

Interventions: Drug: ABI-007 (Abraxane)
Drug: bevacizumab

First Posted Date: 2006-01-25

Last Posted Date: 2019-11-22

Lead Sponsor: Celgene

Target Recruit Count: 208

Registration Number: NCT00281528

Locations: 🇺🇸
Medical Oncology Aultman Hospital, Canton, Ohio, United States
🇺🇸
Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 37 locations

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Placebo
Drug: Standard chemotherapy

First Posted Date: 2006-01-25

Last Posted Date: 2013-07-26

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 684

Registration Number: NCT00281697

Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: bevacizumab

First Posted Date: 2006-01-20

Last Posted Date: 2010-04-22

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 32

Registration Number: NCT00280007

Locations: 🇦🇹
Medizinische Universität Wien, Vienna, Austria

Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: AZD2171
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: Bevacizumab
Drug: Oxaliplatin

First Posted Date: 2006-01-19

Last Posted Date: 2012-10-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 215

Registration Number: NCT00278889

Locations: 🇬🇧
Research Site, Sutton, United Kingdom
🇧🇪
Ressearch Site, Brussels, Belgium

Bevacizumab for Recurrent Malignant Glioma

Phase 2

Completed

Conditions: Recurrent High-Grade Gliomas
Malignant Gliomas

Interventions: Drug: Bevacizumab

First Posted Date: 2006-01-02

Last Posted Date: 2014-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT00271609

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2005-12-21

Last Posted Date: 2015-04-30

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT00267696

Locations: 🇺🇸
The Ohio State University & James Cancer Hospital, Columbus, Ohio, United States

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: bevacizumab
Drug: bevacizumab, erlotinib

First Posted Date: 2005-12-15

Last Posted Date: 2015-12-11

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Target Recruit Count: 700

Registration Number: NCT00265824

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Hôpital Saint Joseph, Paris, France
🇫🇷
Hopital Saint Antoine, Paris, France

and more 38 locations

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Phase 3

Conditions: Metastatic Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Placebo
Drug: Chemotherapy

First Posted Date: 2005-12-06

Last Posted Date: 2013-12-13

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 1237

Registration Number: NCT00262067

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: bevacizumab
Drug: erlotinib HCl
Drug: placebo

First Posted Date: 2005-11-23

Last Posted Date: 2016-04-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 1145

Registration Number: NCT00257608

Locations: 🇺🇸
Siouxland Hem-Onc Assoc LLP, Sioux City, Iowa, United States
🇺🇸
Montana Cancer Specialists, Missoula, Montana, United States
🇺🇸
Coastal Bend Cancer Center, Corpus Christi, Texas, United States

and more 238 locations

Neoadjuvant Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: GM-CSF
Drug: Trastuzumab
Drug: Bevacizumab

First Posted Date: 2005-11-16

Last Posted Date: 2019-02-28

Lead Sponsor: University of California, Irvine

Target Recruit Count: 43

Registration Number: NCT00254592

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy